Supriya Lifescience Limited
Supriya Lifescience Limited (SUPRIYA) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
supriyalifescience.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|
| Sales | 184 Cr | 145 Cr | 200 Cr | 206 Cr |
| Operating expenses (approx.) | 117 Cr | 93 Cr | 127 Cr | 134 Cr |
| EBITDA | 68 Cr | 52 Cr | 73 Cr | 72 Cr |
| OPM % | 36.7% | 35.6% | 36.4% | 34.9% |
| Other income | 3 Cr | 3 Cr | 3 Cr | 3 Cr |
| Interest | 0.42 Cr | 0.51 Cr | 0.41 Cr | 0.49 Cr |
| Depreciation | 6 Cr | 6 Cr | 7 Cr | 7 Cr |
| Profit before tax | 64 Cr | 47 Cr | 68 Cr | 67 Cr |
| Tax % | 21.4% | 26.6% | 26.2% | 25.8% |
| Net profit | 50 Cr | 35 Cr | 50 Cr | 50 Cr |
| EPS (₹) | ₹6.29 | ₹4.32 | ₹6.27 | ₹6.17 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 696 Cr | Sign in for TTM |
| Operating expenses (approx.) | 436 Cr | Sign in for TTM |
| EBITDA | 261 Cr | Sign in for TTM |
| OPM % | 37.4% | Sign in for TTM |
| Other income | 10 Cr | Sign in for TTM |
| Interest | 2 Cr | Sign in for TTM |
| Depreciation | 20 Cr | Sign in for TTM |
| Profit before tax | 248 Cr | Sign in for TTM |
| Tax % | 24.4% | Sign in for TTM |
| Net profit | 188 Cr | Sign in for TTM |
| EPS (₹) | ₹23.35 | Sign in for TTM |
| Dividend payout % | 3.4% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 16 Cr |
| Reserves | 981 Cr |
| Borrowings | — |
| Other liabilities | 116 Cr |
| Total liabilities | 1,112 Cr |
| Fixed assets (net) | 451 Cr |
| CWIP | 148 Cr |
| Investments | 63 Cr |
| Loans & advances | 0.93 Cr |
| Inventories | 118 Cr |
| Trade receivables | 134 Cr |
| Cash & bank | 76 Cr |
| Other assets | 120 Cr |
| Total assets | 1,112 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 165 Cr |
| Cash from investing | -152 Cr |
| Cash from financing | -8 Cr |
| Net cash flow | 4 Cr |
| Free cash flow (OCF − Capex) | 2 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 25.1% |
| ROE % | 18.9% |
| Debtor days | 70 |
| Inventory days | 185 |
| Days payable | 0 |
| Cash conversion cycle | 256 |
| Debt / equity | — |
| Current ratio | 5.32 |
| Net debt / EBITDA | -0.29 |
Compare with peers
Loading peers…